Related Experiment Videos
Chiral drugs: the FDA perspective on manufacturing and control
1Division of Anti-Infective Drug Products, Rockville, MD 20857.
Journal of Pharmaceutical and Biomedical Analysis
|November 1, 1993
Summary
The US Food and Drug Administration (FDA) issued new guidelines in 1992 for developing stereoisomeric drugs. Chemists must now consider drug chirality in analytical controls, manufacturing, stability testing, and drug labeling.
Area of Science:
- Pharmaceutical Chemistry
- Analytical Chemistry
- Drug Development
Background:
- The development of stereoisomeric drugs presents unique analytical and regulatory challenges.
- Chirality is a critical property influencing drug efficacy and safety.
- Previous regulatory frameworks may not have fully addressed stereoisomer-specific considerations.
Purpose of the Study:
- To inform chemists about the implications of the FDA's 1992 policy statement on stereoisomeric drug development.
- To highlight the necessity of incorporating chirality into analytical control strategies.
- To guide the validation of analytical methods for chiral drug substances and products.
Main Methods:
- Review of the FDA's 1992 policy statement on stereoisomeric drug development.
- Analysis of the impact of chirality on various stages of drug development and manufacturing.
- Identification of key areas requiring consideration of stereoisomeric properties.
Main Results:
- The FDA policy mandates that chirality must be considered throughout the drug lifecycle.
- Analytical controls for bulk drug and finished products require stereoisomer-specific validation.
- Stability testing protocols and drug labeling must account for the active ingredient's chirality.
Conclusions:
- Chemists must adapt their practices to comply with new FDA guidelines for chiral drugs.
- Failure to address chirality can impact drug quality, safety, and regulatory approval.
- The policy emphasizes a comprehensive approach to managing stereoisomeric drugs.